drugset / Trial / NCT02237729
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
RandomizedParallel-groupTriple-blindBasic science
Summary
This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers
Timeline
- Start
- 2014-09
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Comparator | Adalimumab-US | Unknown | 40 mg | Subcutaneous |
| Subject | PF-06410293 | Protein / enzyme biologic | 40 mg | Subcutaneous |
Indications
No indication recorded.